We are live on ! Find out more
DRUG

Bright Minds Biosciences
DRUG

47 hedge funds and large institutions have $137M invested in Bright Minds Biosciences in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

38% more funds holding

Funds holding: 34 → 47 (+13)

0.23% more ownership

Funds ownership: 74.11% → 74.34% (+0.23%)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

27% less capital invested

Capital invested by funds: $188M → $137M (-$51.4M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
47
Holders Change
+13
Holders Change %
+38.24%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
22
Increased
7
Reduced
9
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.27M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.72M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$1.03M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$959K
5
Northern Trust
Northern Trust
Illinois
+$768K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$7.45M
2
Millennium Management
Millennium Management
New York
-$2.43M
3
Walleye Capital
Walleye Capital
New York
-$947K
4
Goldman Sachs
Goldman Sachs
New York
-$802K
5
PA
Perceptive Advisors
New York
-$718K
Name Holding Trade Value Shares
Change 		Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$30.2M +$1.03M +34,292 +3%
CAM
2
Cormorant Asset Management
Massachusetts
$27.7M – – –
SCM
3
Sio Capital Management
New York
$13.4M +$143K +4,776 +0.9%
CC
4
Commodore Capital
New York
$13.1M – – –
PA
5
Perceptive Advisors
New York
$11M -$718K -23,959 -5%
VC
6
Vivo Capital
California
$6.57M – – –
BlackRock
7
BlackRock
New York
$5.47M +$6.27M +208,999 +30,826%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$5.22M – – –
Morgan Stanley
9
Morgan Stanley
New York
$4.23M +$165K +5,519 +4%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$3.53M – – –
Millennium Management
11
Millennium Management
New York
$2.91M -$2.43M -81,186 -42%
SSA
12
Schonfeld Strategic Advisors
New York
$1.8M -$198K -6,597 -9%
IC
13
Ikarian Capital
Texas
$1.71M – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.5M +$1.72M +57,521 New
Walleye Capital
15
Walleye Capital
New York
$1.4M -$947K -31,592 -37%
ACP
16
Acuta Capital Partners
California
$1.27M -$338K -11,274 -19%
Vanguard Group
17
Vanguard Group
Pennsylvania
$835K +$959K +31,983 New
PIM
18
Platinum Investment Management
Australia
$739K – – –
Northern Trust
19
Northern Trust
Illinois
$669K +$768K +25,626 New
State Street
20
State Street
Massachusetts
$644K +$739K +24,655 New
BFM
21
Boothbay Fund Management
New York
$500K – – –
AI
22
AdvisorShares Investments
Maryland
$378K +$95.9K +3,200 +28%
RAM
23
Readystate Asset Management
Illinois
$365K +$419K +13,975 New
N
24
Nuveen
North Carolina
$326K +$374K +12,487 New
Charles Schwab
25
Charles Schwab
California
$303K +$348K +11,604 New
1
2 3

DRUG Hedge Fund Activity: Q2 2025 in Review

47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q2 2025, worth a combined $137M — down 27% from $188M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new DRUG positions and 9 closed out — a net gain of 13 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was BlackRock, adding an estimated $6.27M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.45M sold.

  • 47 institutional investors held Bright Minds Biosciences (DRUG) as of Q2 2025, up from 34 in Q1 2025.
  • Funds reported $137M of Bright Minds Biosciences stock for Q2 2025, down 27% quarter-over-quarter.
  • 22 funds opened new Bright Minds Biosciences positions in Q2 2025 and 9 closed out, a net change of +13 holders.
  • The largest Bright Minds Biosciences buyer in Q2 2025 was BlackRock, an estimated $6.27M added.
  • The largest Bright Minds Biosciences seller in Q2 2025 was RA Capital Management, an estimated $7.45M sold.

Based on aggregated 13F filings for Q2 2025.